World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
39222
World Ranking
16386
National Ranking
8244

Neil P. Shah publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Neil P. Shah sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 401 publications — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Neil P. Shah D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Neil P. Shah sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Neil P. Shah is affiliated with the University of California, San Francisco in the United States. Their primary field of study is Medicine, with a significant focus on Hematology, Genetics, and Oncology, as well as Surgery and Rheumatology. Shah's research reflects a broad engagement with the study of blood-related diseases and cancer.

The scientist's main research topics include:

  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Acute Myeloid Leukemia Research
  • HER2/EGFR in Cancer Research
  • Eosinophilic Disorders and Syndromes
  • Venous Thromboembolism Diagnosis and Management
  • Diagnosis and Treatment of Venous Diseases

Shah has contributed to multiple publications spanning several recognized medical journals. The most frequent venues for their work include:

  • Blood
  • Leukemia
  • European Journal of Medicinal Chemistry
  • Haematologica
  • Cureus

Among their recent papers are:

  • Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia, 2020, JAMA Oncology
  • Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia, 2022, American Journal of Hematology
  • Six-Month Outcomes of Mechanical Thrombectomy for Treating Deep Vein Thrombosis: Analysis from the 500-Patient CLOUT Registry, 2023, CardioVascular and Interventional Radiology
  • Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials, 2024, Leukemia

Shah frequently collaborates with other researchers in their field. Notable coauthors include:

  • Michael J. Mauro
  • Jorge E. Cortés
  • Michael W. Deininger
  • Javier Pinilla-Ibarz
  • Delphine Réa

Best Publications

  • Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

    Neil P. Shah;Chris Tran;Francis Y. Lee;Ping Chen

  • Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato

  • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

    Neil P. Shah;John M. Nicoll;Bhushan Nagar;Mercedes E. Gorre

  • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

    Hagop Kantarjian;Neil P. Shah;Andreas Hochhaus;Jorge Cortes

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • Dynamics of chronic myeloid leukaemia.

    Franziska Michor;Timothy P. Hughes;Yoh Iwasa;Susan Branford

  • Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Jorge E. Cortes;Giuseppe Saglio;Hagop M. Kantarjian;Michele Baccarani

  • Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

    Todd A. Carter;Lisa M. Wodicka;Neil P. Shah;Anne Marie Velasco

  • Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Jorge E Cortes;Hagop M Kantarjian;Neil P. Shah;Dale Bixby

  • Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

    Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst

  • Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

    Catherine C. Smith;Qi Wang;Chen Shan Chin;Sara Salerno

  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

    Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton

  • Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Hagop M. Kantarjian;Neil P. Shah;Jorge E. Cortes;Michele Baccarani

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle

    J. B. M. Jowett;V. Planelles;B. Poon;N. P. Shah

  • Gene expression changes associated with progression and response in chronic myeloid leukemia

    Jerald P. Radich;Hongyue Dai;Mao Mao;Vivian Oehler

  • Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

    Neil P. Shah;Hagop M. Kantarjian;Dong Wook Kim;Delphine Réa

  • Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

    Jorge E Cortes;Philippe Rousselot;Dong Wook Kim;Ellen Ritchie

  • Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

    Hagop M Kantarjian;Ricardo Pasquini;Nelson Hamerschlak;Philippe Rousselot

  • Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

    A. Hochhaus;M. Baccarani;M. Deininger;J. F. Apperley

Frequent Co-Authors

Jorge E. Cortes
Jorge E. Cortes Augusta University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Michael W. Deininger
Michael W. Deininger University of Utah
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Michele Baccarani
Michele Baccarani University of Bologna
Francois Guilhot
Francois Guilhot Grenoble Alpes University
Victor M. Rivera
Victor M. Rivera Takeda (Japan)
Charles L. Sawyers
Charles L. Sawyers Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering medicine in the USA, there are many related online degrees and career pathways worth exploring. These options can offer faster, flexible, and more affordable routes within the healthcare sector.

If you're interested in mental health, some of the shortest online pmhnp programs allow you to quickly become a Psychiatric Mental Health Nurse Practitioner, expanding your career potential. Similarly, those wanting to learn about the business side of healthcare can pursue a healthcare administration degree online, which prepares graduates for management roles.

For advanced leadership positions, explore online mha programs affordable from accredited universities that provide high-quality education at a lower cost. If your goal is becoming a clinical leader, the cheapest dnp online programs can help you achieve a Doctor of Nursing Practice degree without excessive student debt.

These online programs can provide valuable credentials for diverse healthcare careers while offering flexibility for working adults or those seeking cost-effective pathways into the industry.

Best Scientists Citing Neil P. Shah

Trending Scientists

Recently Published Articles